Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] LIG D&A (079550) – Hanwha Investment & Securities | 3Q25 Review · Secured Growth Materialization · Expanding Export Share / 2025-11-07 Research
  • [Research] Samsung Electro-Mechanics (009150) – Shinhan Securities | High-Value Order Expansion · ASP Growth · Earnings Upward Revision / 2026-07-31 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Memory Pricing · ADR Listing · Valuation Re-rating / 2026-03-23 Research
  • [Research] LigaChem Biosciences (141080) – Eugene Investment & Securities | Pipeline Clinical Progression · Licensing Revenue · Earnings Turnaround / 2025-02-17 Research
  • [Research] SK hynix (000660 / SKHY) – Shinhan | Memory ASP · Supply Tightness · Pricing Power / 2026-01-30 Research
  • [Research] LIG D&A (079550) – Hanwha Investment & Securities | 4Q25 Review · Ghost Robotics Impairment Cleared · Margin Expansion / 2026-02-23 Research
  • [Research] SK hynix (000660 / SKHY) – Hana | LPDDR Demand · Mobile DRAM Tightness · Earnings Growth / 2026-04-24 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Solidigm Monetization · Shareholder Returns · Valuation Appeal / 2026-08-11 Research

[Research] SK hynix (000660 / SKHY) – Kyobo | AI Server Demand · Memory ASP · High-Value Product Mix / 2026-01-30

Posted on January 30, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Kyobo Securities

Analyst : Boyoung Choi

Investment Rating : Buy (Maintained)

Target Price : 1,100,000 KRW (Raised)

Core Momentum : Robust AI server and hyperscaler investment is expected to sustain broad-based DRAM and NAND price increases, while HBM4 and next-generation high-value memory products support continued margin and earnings expansion.

📊 1. [Valuation & Key Financial Metrics]

  • Target Price: 1,100,000 KRW (Raised)
  • Investment Rating: Buy (Maintained)
  • 2026E Financial Outlook: Revenue 184.88 trillion KRW, Operating Profit 122.11 trillion KRW, Net Income 104.59 trillion KRW
  • EPS: 143,611 KRW (2026E)
  • Valuation Multiples: P/E 6.0x, P/B 2.9x, EV/EBITDA 4.3x, ROE 62.4% (Based on 2026E)

🚀 2. [Market Opportunities & Business Outlook]

  • 4Q25 Review: Revenue reached 32.83 trillion KRW (+66% YoY, +34% QoQ) and operating profit hit 19.17 trillion KRW (+137% YoY, +68% QoQ, OPM +58%), significantly beating consensus estimates (Revenue 31 trillion KRW, Operating Profit 16.4 trillion KRW). Estimated DRAM B/G +3%, ASP +25%, operating profit 16.6 trillion KRW (OPM +67%) / NAND B/G +11%, ASP +31%, operating profit 2.156 trillion KRW (OPM +29%).
  • Shareholder Returns & HBM Competitiveness: Executed robust shareholder return policies including a special dividend of 2.1 trillion KRW and a treasury share cancellation worth 12.2 trillion KRW. HBM4 targets required performance based on 1b technology and aims to secure yields comparable to HBM3E using Advanced MR-MUF.
  • 1Q26 Preview: Operating profit projected at 24.6 trillion KRW (+230% YoY, +8.4% QoQ, OPM +63%) on revenue of 38.9 trillion KRW. Ongoing price increases expected with [DRAM] B/G -1%, ASP +21%, operating profit 20.8 trillion KRW (OPM +71%) and [NAND] B/G -3%, ASP +25%, operating profit 3.722 trillion KRW (OPM +42%).
  • Portfolio Diversification: Accelerating 1nm transition to expand high-value AI memory product mix including SoCAMM2 and GDDR7, while proactively addressing ultra-high capacity AI demand through 321-layer NAND, QLC eSSD utilization, and 245TB product development.

📝 Editor’s Comment (Perspective)

The analyst views SK hynix as a company capturing sharp earnings growth by capitalizing on robust infrastructure investment demand from AI servers and hyperscalers, driving both shipment expansion and price increases (ASP) across memory segments (DRAM and NAND). The analyst emphasizes strong shareholder return policies and high-value portfolio shifts alongside near-term earnings beats.

To verify this investment thesis, one should monitor whether 1Q26 results meet expectations (Revenue 38.9 trillion KRW, Operating Profit 24.6 trillion KRW) to sustain operating leverage, if target yields for HBM4 mass production are successfully secured, and how 1nm migration and AI product mix improvements translate into actual profitability metrics. These metrics can be tracked through upcoming quarterly earnings reports, official IR materials, and regulatory filings via DART/KRX.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – Hana | Memory Pricing · Cash Flow · Shareholder Returns / 2026-01-30
Next Post: [Research] SK hynix (000660 / SKHY) – DS Investment | Server Memory Demand · HBM3E Pricing · Margin Expansion / 2026-01-30

Related Posts

  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Hyperscaler Capex · Custom HBM · Inference Memory Demand / 2026-05-04 Research
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | SDC Stake Monetization Pursuit · North America ESS & Europe EV Order Acceleration · Operating Profit Turnaround / 2026-04-29 Research
  • [Research] LIG D&A (079550) – iM Securities | Export Pipeline · CapEx & Hiring Expansion · Global Air Defense Growth / 2026-08-07 Research
  • [Research] Samsung SDI (006400) – Kiwoom Securities | ESS & BBU Momentum · Europe Market Share Recovery · 4Q26 Turnaround / 2026-04-29 Research
  • [Research] Hanwha Ocean (042660) – Yuanta | Merchant Mix Improvement · CPSP Project Value · MASGA Catalysts / 2026-07-06 Shipbuilding
  • [Research] Samsung Biologics (207940) – Daishin Securities | Peptide Market Entry · Global Footprint Expansion · Modality Diversification / 2026-07-21 Research
  • [Research] Alteogen (196170) – Daishin Securities | Keytruda Qlex Commercial Milestones · RNA Modality Expansion · Platform Re-rating / 2026-08-10 Research
  • [Research] Celltrion (068270) – Daishin Securities | Merger Noise Resolution · Portfolio Expansion Leverage · CMO Revenue Visibility / 2026-05-19 Research
  • [Research] SK hynix (000660 / SKHY) – Shinhan | ADR Listing · HBM Pricing · Valuation Re-rating / 2026-06-30 Research
  • [Research] Celltrion (068270) – DS Investment & Securities | 2nd-Gen Biosimilar Penetration · COGS Ratio Stabilization · Global Capacity Expansion / 2026-05-07 Research
  • [Research] LIG D&A (079550) – Daishin Securities | 2Q26 Review · Backlog Realization · Export Margin Expansion / 2026-08-10 Research
  • [Research] Hanwha Ocean (042660) – DS Investment & Securities | Low-Price Mix Reduction · Merchant Margin Step-Up · MASGA & Defense Pipeline / 2026-04-28 Research
  • [Research] Hanwha Ocean (042660) – Daishin | Merchant Vessel Margin · FX Impact · US Navy Logistics Synergy / 2026-07-29 Research
  • [Research] Samsung Biologics (207940) – Kiwoom Securities | Plant 5 & Rockville Ramp-up · Guidance Upside · 4Q Earnings Concentration / 2026-07-24 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme